These effects can be achieved by the IKBKE inhibitor CYT387 (Figure 8), suggesting that the IKBKE-RRM2 axis plays a pivotal role in regulating RCC progression and sunitinib resistance and that IKBKE may be a potential target for the treatment of RCC. Here, RRM2 is linked to renal cell carcinoma.